drugset / Trial / NCT04942340

Turning Dexmedetomidine Into a Powerful Anesthetic That Can be Rapidly and Completely Reversed

NCT04942340

Phase 1 Withdrawn University of Chicago
RandomizedParallel-groupSingle-blindTreatment

Summary

In this study, the investigators will explore Atipamezole \& caffeine's ability to facilitate the emergence from anesthesia. Each subject will visit UChicago 4 times. The first time for informed consent. The second time for a complete physical exam to ensure that the subjects are healthy. Then there are 2 sedation sessions. Subjects get an honorarium for each sedation session.

Timeline

Start
2023-05
Primary completion
2026-04
Completion
2026-05

Drugs

EvaluationDrugModalityDoseRoute
Comparator Atipamezole Small molecule 2 g/kg Intravenous
Comparator Caffeine Small molecule 15 mg/kg Intravenous
Comparator Dexmedetomidine Other / unclassified 15 mg/kg Intravenous

Indications

No indication recorded.